Moderna Settles for $950 Million with Arbutus, Eyes Future Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 8 hours ago
0mins
Should l Buy MRNA?
Source: Benzinga
- Settlement Agreement: Moderna has reached a $950 million settlement with Arbutus Biopharma and Roivant's Genevant Sciences, resolving all litigation related to its COVID-19 vaccine Spikevax and mRESVIA product, which is expected to be paid in the third quarter, significantly alleviating the company's legal burdens.
- Potential Additional Payments: Depending on the outcome of a legal appeal regarding government-contractor immunity, Moderna may face up to $1.3 billion in additional payments, which would represent the largest disclosed patent settlement in the pharmaceutical industry, further impacting the company's financial outlook.
- Future Growth Outlook: CEO Stéphane Bancel emphasized that resolving this legacy issue allows the company to focus on the future, with expectations to end 2026 with $4.5 billion to $5 billion in cash and equivalents, aiming to return to revenue growth in 2026 and achieve breakeven by 2028.
- Positive Market Reaction: The settlement amount was better than feared, leading to an 8.85% increase in Moderna's stock price during Wednesday's premarket trading, currently at $54.24, close to its 52-week high, reflecting investor confidence in the company's future prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall
20 Analyst Rating
1 Buy
16 Hold
3 Sell
Hold
Current: 49.830
Low
17.00
Averages
32.47
High
63.00
Current: 49.830
Low
17.00
Averages
32.47
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
U.S. Markets Increased on Wednesday; Moderna Led the Gains
- U.S. Stock Market Performance: Stock indexes in the U.S. closed higher on Wednesday, indicating a positive market trend.
- Index Gains: The S&P 500 gained 1.29%, the Dow Jones increased by 0.78%, and the Nasdaq rose by 0.49%.
See More
Moderna-Arbutus-Genevant Patent Agreement: Wall Street Views It as Suboptimal, Yet Alleviates Pressure on MRNA Shares
Settlement Announcement: Moderna has entered into a $2.25 billion settlement with Arbutus and Genevant regarding a vaccine patent dispute, with a payment of $950 million due in Q3 2026.
Stock Market Reaction: Following the settlement news, Moderna's shares rose by 16%, reflecting a shift in investor sentiment from bearish to bullish.
Future Liabilities: The settlement resolves all enforcement actions against Moderna but leaves a contingent liability of up to $1.3 billion if further litigation affirms liability.
Analyst Insights: Analysts view the settlement as a positive development that alleviates uncertainty for Moderna's stock, while maintaining a neutral rating with a price target of $41.
See More
Midday Market Moves: Notable Stock Fluctuations
- CoreWeave Partnership: CoreWeave's stock surged 8% following a multiyear agreement with Perplexity, which will utilize CoreWeave's platform for next-generation inference workloads, enhancing its competitive edge in the cloud market.
- Broadcom Earnings Anticipation: Broadcom shares rose 2% as investors await its fiscal first-quarter earnings report, with analysts projecting earnings of $2.03 per share and revenue of $19.18 billion, indicating strong market confidence in its performance.
- Dow Inc Upgrade Impact: Dow Inc's stock increased by 4% after KeyBanc upgraded its rating from sector weight to overweight, citing that rising oil prices will benefit U.S. ethylene producers, reflecting optimistic market expectations for its profitability.
- Moderna Lawsuit Settlement: Moderna's shares climbed 12% after the company agreed to pay up to $2.25 billion to settle a lawsuit with Arbutus Biopharma and Genevant Sciences over a Covid vaccine patent, demonstrating proactive legal risk management.
See More
US Stocks Rise on Economic Strength Amid Iran War Concerns
- Strong Economic Data: The February ADP employment report revealed an addition of 63,000 jobs, surpassing expectations of 50,000, indicating continued growth in the labor market and bolstering investor confidence in economic recovery.
- Service Sector Expansion: The US services index unexpectedly rose to 56.1, marking the fastest expansion in 3.5 years, while service price pressures fell to an 11-month low, demonstrating economic resilience that could further drive stock market gains.
- International Situation Impact: Reports of Iran making indirect contact with the US to negotiate an end to the war boosted market sentiment, although Iranian media denied the claims, the hope for an early resolution to the conflict remains.
- Oil Price Volatility: Despite crude oil prices being affected by the Iranian drone attack and the closure of the Strait of Hormuz leading to production cuts in Iraq, the market estimates a risk premium of $18 per barrel, reflecting heightened concerns over energy supply.
See More
Wall Street Rallies on Optimism Over US-Iran Diplomatic Talks
- Market Rally: Wall Street experienced a relief rally on Wednesday, driven by optimism surrounding potential US-Iran diplomatic talks, with the Nasdaq 100 gaining 1.5% to 25,100, indicating investor confidence in future economic stability.
- Oil Price Decline: Following two consecutive days of gains, Brent crude fell 0.5% to $81.00 per barrel and WTI crude slipped 0.8% to $74.07, reflecting the impact of diplomatic optimism on the energy market.
- Volatility Index Drop: The CBOE Volatility Index plunged 11.6% to 20.84, indicating a rise in market risk appetite and a decrease in demand for safe-haven assets, further fueling the stock market's upward momentum.
- Stable Treasury Yields: The 10-year U.S. Treasury yield held steady at 4.07%, suggesting that as risk appetite increases, demand for safe assets is capped, reflecting a positive outlook on economic prospects.
See More
US Stocks Fluctuate Slightly Amid Oil Price Pressures
- Market Movements: The S&P 500 Index rose by 0.03%, while the Dow Jones Industrial Average fell by 0.11%, and the Nasdaq 100 Index increased by 0.63%, reflecting a slight recovery in the market following reports of indirect contact between Iran and the US to negotiate an end to the conflict, despite ongoing global trade tensions.
- Employment Data Impact: The February ADP employment report indicated an increase of 63,000 jobs, surpassing expectations of 50,000, suggesting a resilient labor market that may support the stock market, while also raising concerns about Federal Reserve policy direction.
- Oil Price Fluctuations: Crude oil prices fell by over 1% after Iran proposed discussions with the US to end the conflict, compounded by Treasury Secretary's comments on potential 15% tariffs on imports, adding to market uncertainty.
- Economic Outlook: This week, the market will focus on US-Iran war news, corporate earnings, and economic data, with expectations for a slight decline in the February ISM services index and an increase of 3,000 in initial unemployment claims to 215,000, highlighting the complexities of economic recovery.
See More
U.S. Markets Increased on Wednesday; Moderna Led the Gains
- U.S. Stock Market Performance: Stock indexes in the U.S. closed higher on Wednesday, indicating a positive market trend.
- Index Gains: The S&P 500 gained 1.29%, the Dow Jones increased by 0.78%, and the Nasdaq rose by 0.49%.
See More
Moderna-Arbutus-Genevant Patent Agreement: Wall Street Views It as Suboptimal, Yet Alleviates Pressure on MRNA Shares
Settlement Announcement: Moderna has entered into a $2.25 billion settlement with Arbutus and Genevant regarding a vaccine patent dispute, with a payment of $950 million due in Q3 2026.
Stock Market Reaction: Following the settlement news, Moderna's shares rose by 16%, reflecting a shift in investor sentiment from bearish to bullish.
Future Liabilities: The settlement resolves all enforcement actions against Moderna but leaves a contingent liability of up to $1.3 billion if further litigation affirms liability.
Analyst Insights: Analysts view the settlement as a positive development that alleviates uncertainty for Moderna's stock, while maintaining a neutral rating with a price target of $41.
See More
Midday Market Moves: Notable Stock Fluctuations
- CoreWeave Partnership: CoreWeave's stock surged 8% following a multiyear agreement with Perplexity, which will utilize CoreWeave's platform for next-generation inference workloads, enhancing its competitive edge in the cloud market.
- Broadcom Earnings Anticipation: Broadcom shares rose 2% as investors await its fiscal first-quarter earnings report, with analysts projecting earnings of $2.03 per share and revenue of $19.18 billion, indicating strong market confidence in its performance.
- Dow Inc Upgrade Impact: Dow Inc's stock increased by 4% after KeyBanc upgraded its rating from sector weight to overweight, citing that rising oil prices will benefit U.S. ethylene producers, reflecting optimistic market expectations for its profitability.
- Moderna Lawsuit Settlement: Moderna's shares climbed 12% after the company agreed to pay up to $2.25 billion to settle a lawsuit with Arbutus Biopharma and Genevant Sciences over a Covid vaccine patent, demonstrating proactive legal risk management.
See More
US Stocks Rise on Economic Strength Amid Iran War Concerns
- Strong Economic Data: The February ADP employment report revealed an addition of 63,000 jobs, surpassing expectations of 50,000, indicating continued growth in the labor market and bolstering investor confidence in economic recovery.
- Service Sector Expansion: The US services index unexpectedly rose to 56.1, marking the fastest expansion in 3.5 years, while service price pressures fell to an 11-month low, demonstrating economic resilience that could further drive stock market gains.
- International Situation Impact: Reports of Iran making indirect contact with the US to negotiate an end to the war boosted market sentiment, although Iranian media denied the claims, the hope for an early resolution to the conflict remains.
- Oil Price Volatility: Despite crude oil prices being affected by the Iranian drone attack and the closure of the Strait of Hormuz leading to production cuts in Iraq, the market estimates a risk premium of $18 per barrel, reflecting heightened concerns over energy supply.
See More
Wall Street Rallies on Optimism Over US-Iran Diplomatic Talks
- Market Rally: Wall Street experienced a relief rally on Wednesday, driven by optimism surrounding potential US-Iran diplomatic talks, with the Nasdaq 100 gaining 1.5% to 25,100, indicating investor confidence in future economic stability.
- Oil Price Decline: Following two consecutive days of gains, Brent crude fell 0.5% to $81.00 per barrel and WTI crude slipped 0.8% to $74.07, reflecting the impact of diplomatic optimism on the energy market.
- Volatility Index Drop: The CBOE Volatility Index plunged 11.6% to 20.84, indicating a rise in market risk appetite and a decrease in demand for safe-haven assets, further fueling the stock market's upward momentum.
- Stable Treasury Yields: The 10-year U.S. Treasury yield held steady at 4.07%, suggesting that as risk appetite increases, demand for safe assets is capped, reflecting a positive outlook on economic prospects.
See More
US Stocks Fluctuate Slightly Amid Oil Price Pressures
- Market Movements: The S&P 500 Index rose by 0.03%, while the Dow Jones Industrial Average fell by 0.11%, and the Nasdaq 100 Index increased by 0.63%, reflecting a slight recovery in the market following reports of indirect contact between Iran and the US to negotiate an end to the conflict, despite ongoing global trade tensions.
- Employment Data Impact: The February ADP employment report indicated an increase of 63,000 jobs, surpassing expectations of 50,000, suggesting a resilient labor market that may support the stock market, while also raising concerns about Federal Reserve policy direction.
- Oil Price Fluctuations: Crude oil prices fell by over 1% after Iran proposed discussions with the US to end the conflict, compounded by Treasury Secretary's comments on potential 15% tariffs on imports, adding to market uncertainty.
- Economic Outlook: This week, the market will focus on US-Iran war news, corporate earnings, and economic data, with expectations for a slight decline in the February ISM services index and an increase of 3,000 in initial unemployment claims to 215,000, highlighting the complexities of economic recovery.
See More
